These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 28358927)

  • 21. Structural insights into drug transport by an aquaglyceroporin.
    Chen W; Zou R; Mei Y; Li J; Xuan Y; Cui B; Zou J; Wang J; Lin S; Zhang Z; Wang C
    Nat Commun; 2024 May; 15(1):3985. PubMed ID: 38734677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of Trypanosoma brucei MRPA in melarsoprol susceptibility.
    Alibu VP; Richter C; Voncken F; Marti G; Shahi S; Renggli CK; Seebeck T; Brun R; Clayton C
    Mol Biochem Parasitol; 2006 Mar; 146(1):38-44. PubMed ID: 16343658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trypanosoma brucei and T. vivax: salicylhydroxamic acid and glycerol treatment of acute and chronically infected rats.
    van der Meer C; Versluijs-Broers JA
    Exp Parasitol; 1986 Aug; 62(1):98-113. PubMed ID: 3720904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the in vitro drug sensitivity of Trypanosoma brucei gambiense strains from West and Central Africa isolated in the periods 1960-1995 and 1999-2004.
    Likeufack AC; Brun R; Fomena A; Truc P
    Acta Trop; 2006 Nov; 100(1-2):11-6. PubMed ID: 17078916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The phenomenon of treatment failures in Human African Trypanosomiasis.
    Brun R; Schumacher R; Schmid C; Kunz C; Burri C
    Trop Med Int Health; 2001 Nov; 6(11):906-14. PubMed ID: 11703845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional characterization of three aquaglyceroporins from Trypanosoma brucei in osmoregulation and glycerol transport.
    Bassarak B; Uzcátegui NL; Schönfeld C; Duszenko M
    Cell Physiol Biochem; 2011; 27(3-4):411-20. PubMed ID: 21471730
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-throughput decoding of antitrypanosomal drug efficacy and resistance.
    Alsford S; Eckert S; Baker N; Glover L; Sanchez-Flores A; Leung KF; Turner DJ; Field MC; Berriman M; Horn D
    Nature; 2012 Jan; 482(7384):232-6. PubMed ID: 22278056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Veterinary link to drug resistance in human African trypanosomiasis?
    Barrett MP
    Lancet; 2001 Aug; 358(9282):603-4. PubMed ID: 11530144
    [No Abstract]   [Full Text] [Related]  

  • 29. Trypanosoma brucei: lack of cross-resistance to melarsoprol in vitro by cymelarsan-resistant parasites.
    Scott AG; Tait A; Turner CM
    Exp Parasitol; 1997 Jul; 86(3):181-90. PubMed ID: 9225768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential virulence of Trypanosoma brucei rhodesiense isolates does not influence the outcome of treatment with anti-trypanosomal drugs in the mouse model.
    Ndung'u K; Murilla GA; Thuita JK; Ngae GN; Auma JE; Gitonga PK; Thungu DK; Kurgat RK; Chemuliti JK; Mdachi RE
    PLoS One; 2020; 15(11):e0229060. PubMed ID: 33151938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Further evidence for a link between melarsoprol resistance and P2 transporter function in African trypanosomes.
    de Koning HP; MacLeod A; Barrett MP; Cover B; Jarvis SM
    Mol Biochem Parasitol; 2000 Feb; 106(1):181-5. PubMed ID: 10743623
    [No Abstract]   [Full Text] [Related]  

  • 32. [Human African trypanosomiasis].
    Dumas M; Bouteille B
    C R Seances Soc Biol Fil; 1996; 190(4):395-408. PubMed ID: 8952890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro drug sensitivity of Trypanosoma gambiense isolates.
    Brun R; Baeriswyl S; Kunz C
    Acta Trop; 1989 Oct; 46(5-6):369-76. PubMed ID: 2575872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of mutant P2 adenosine transporter (TbAT1) gene in Trypanosoma brucei gambiense isolates from northwest Uganda using allele-specific polymerase chain reaction.
    Nerima B; Matovu E; Lubega GW; Enyaru JC
    Trop Med Int Health; 2007 Nov; 12(11):1361-8. PubMed ID: 18045263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Innate lack of susceptibility of Ugandan Trypanosoma brucei rhodesiense to DL-alpha-difluoromethylornithine (DFMO).
    Iten M; Matovu E; Brun R; Kaminsky R
    Trop Med Parasitol; 1995 Sep; 46(3):190-4. PubMed ID: 8533023
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential sensitivity of Trypanosoma brucei rhodesiense isolates to in vitro lysis by arsenicals.
    Yarlett N; Goldberg B; Nathan HC; Garofalo J; Bacchi CJ
    Exp Parasitol; 1991 Feb; 72(2):205-15. PubMed ID: 1849084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Melarsoprol].
    Simon F
    Med Trop (Mars); 1999; 59(4):331-2. PubMed ID: 10816741
    [No Abstract]   [Full Text] [Related]  

  • 38. Front-line glioblastoma chemotherapeutic temozolomide is toxic to Trypanosoma brucei and potently enhances melarsoprol and eflornithine.
    Steverding D; Rushworth SA
    Exp Parasitol; 2017 Jul; 178():45-50. PubMed ID: 28552794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Trypanosoma brucei ORFeome-Based Gain-of-Function Library Identifies Genes That Promote Survival during Melarsoprol Treatment.
    Carter M; Gomez S; Gritz S; Larson S; Silva-Herzog E; Kim HS; Schulz D; Hovel-Miner G
    mSphere; 2020 Oct; 5(5):. PubMed ID: 33028684
    [No Abstract]   [Full Text] [Related]  

  • 40. Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda.
    Matovu E; Enyaru JC; Legros D; Schmid C; Seebeck T; Kaminsky R
    Trop Med Int Health; 2001 May; 6(5):407-11. PubMed ID: 11348535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.